Open Access
Subscription or Fee Access
COVID-19: An Emerging Global Threat
Abstract
The emergence of COVID-19 in Wuhan, Hubei Province, China in December 2019 has worsened global health worries. It is now declared by World Health Organization (WHO) as a Public Health Emergency of International Concern (PHEIC). Till 22 March 2021, there have been 122,524,424 confirmed cases of COVID-19 globally, with 2,703,620 deaths, and more than 216 countries are suffering from this fatal virus. The transmission of coronavirus occurs via droplets, filthy hands, and surfaces with an incubation period of 2 to14 days. The speed of the transmission of this lethal infection airs a severe danger to public health. To alleviate COVID-19 patients, it is imperative, to begin with, the initial diagnosis, isolation, and supportive management. As a part of the massive worldwide response to limit and contain the pandemic, an important consideration was placed on producing research intelligence to monitor evidence-based responses to confine the SARS-CoV-2 virus. Currently, the novel variants of the COVID-19 have been detected in the UK, South Africa, and Brazil. These variants represented several mutations on spike proteins. A potential escalation in the transmission of SARS-CoV-2 infection in humans due variants development has raised a serious concern. The present review highlights the general characteristics of SARS-CoV-2, pathogenesis, transmission, diagnosis, epidemiology, and treatment of COVID-19 infection. It also focuses on the current information on new variants of coronavirus-19, emergency use authorization of COVID-19 vaccine, and regulatory requirement for developing and introducingCOVID-19 vaccines in the Indian market.
Keywords
References
Lai CC, Liu YH, Wang CY, Wang YH, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect. 2020 Jun;53(3):404–412. https://doi.org/10.1016/j.jmii.2020.02.012.
Lupia T, Scabini S, Mornese S, et al. 2019 novel coronavirus (2019-nCoV) outbreak: A new challenge. J Glob Antimicrob Re. 2020; 21: 22–7p.
Shereen MA, Khan S, Kazmi A, Bashir,N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020: 24; 91–8p.
Han Q, Lin Q, Jin, S You, et al. Coronavirus 2019-nCoV: A brief perspective from the front line. J Infect. 2020; 80(4): 373–377.
Devaux CA, Rolain JM, Colson P, et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob. Agent, https://doi.org/10.1016/j.ijantimicag.2020.105938.
Ghinai I, McPherson TD, Hunter JC, et al. First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet. 2020; 395: (10230), 1137–44p.
Li X, Geng M, Peng Y, et al. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020, 10(2),102–108.
Sun J, He WT, Wang L, et al. COVID-19: Epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med. 2020; 26(5): 483–95p.
Wu D, Wu T, Liu Q, et al. The SARS-CoV-2 outbreak: What we know. Int J Infect Dis. 2020; 12 (94): 44–8p.
Tang B, Bragazzi NL, Li Q, et al. An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov). Infect Dis Model. 2020: 5; 248–55p.
Su S, Wong G, Sh, W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016; 24(6): 490-502.
Li H, Liu SM, Yu XH, et al. Coronavirus disease 2019 (COVID-19): current status and future perspective. Int J Antimicrob Agents. 2020 May;55(5):105951. https://doi.org/10.1016/j.ijantimicag.2020.105951.
Wang LS, Wang YR, Ye DW, et al. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agent. 2020 Jun;55(6):105948. https://doi.org/10.1016/j.ijantimicag.2020.105948.
Chen J. Pathogenicity and transmissibility of 2019-nCoV—A quick overview and comparison with other emerging viruses. Microb Infect. 2020: 22(2); 69–71.
Rothan HA, Byrareddy SNJ. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020; 109: 102433.
WHO. Coronavirus disease (COVID-19) pandemic https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (accessed on 11/06/20).
WHO. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/?gclid (accessed on 22/03/21).
WHO. https://who.sprinklr.com/region/searo/country/in (accessed on 11/06/20).
WHO. https://covid19.who.int/region/searo/country/in(accessed on 22/03/21).
Hui DSC, Zumla A. Severe acute respiratory syndrome: Historical, epidemiologic, and clinical features. Infect Dis Clin North Am. 2019; 33(4): 869-89p.
Yang Y, Peng F, Wang R., et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun. 2020; 09: 102434.
Zhang R, Wang X, Ni L, et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020; 250: 117583.
Petrosillo N, Viceconte G, Ergonul O, et al. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020 Jun;26(6):729-734. https://doi.org/10.1016/j.cmi.2020.03.026.
Ye G, Pan Z, Pan, Y. et al. Clinical characteristics of severe acute respiratory syndrome coronavirus-2 reactivation. J Infect. 2020; 80(5): e14–e17.
Tian S, Hu N, Lou, J. et al. Characteristics of COVID-19 infection in Beijing. J Infect. 2020; 80(4): 401–6p.
Huang C, Wang Y, Li, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 2020; 395 (10223):497–506p.
Rodriguez-Morales AJ, Cardona-Ospina JA. Villamizar-Peña R, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020; 34: 101623.
Kooraki S, Hosseiny M, Myers L, et al. Coronavirus (COVID-19) outbreak: What the department of radiology should know. J Am Coll Radiol. 2020; 17(4):447–51p.
Huang Z, Zhao S, Li Z, et al. The battle against coronavirus disease 2019 (COVID-19): Emergency management and infection control in a radiology department. J Am Coll Radiol. 2020; Mar 24; S1546-1440(20)30285-4.doi:10.1016/j.jacr.2020.03.011.
Zhai P, Ding Y, Wu X, et al. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents, 2020 May;55(5):105955. https://doi.org/10.1016/j.ijantimicag.2020.105955.
Choon-Huat Koh, G Hoenig H. How should the rehabilitation community prepare for 2019-nCoV? Arch Phys Med Rehabil. 2020 Jun;101(6):1068-1071. https://doi.org/10.1016/j.apmr.2020.03.003.
Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: The reality and challenges. 2020 Jun;53(3):436–443. J Microbiol Immunol Infect. https://doi.org/10.1016/j.jmii.2020.03.034.
Sallard E, Lescure FX, Yazdanpanah Y, et al. Type 1 interferons as a potential treatment against COVID-19. Antivir Res.2020,178, 104791.
Sahraei Z, Shabani M, Shokouhi S, et al. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents. 2020; 55(4):105945.
AminJafari A, Ghasemi S.The possible of immunotherapy for COVID-19: A systematic review. Int. Immunopharmacol. 2020: 83:106455.
NIH. What's New in the Guidelines. https://www.covid19treatmentguidelines.nih.gov/whats-new/ (accessed on 23/05/20)
NIH. NIH clinical trial testing antiviral remdesivir plus anti-inflammatory drug baricitinib for COVID-19 begins. https://www.nih.gov/news-events/news-releases/nih-clinical-trial-testing-antiviral-remdesivir-plus-anti-inflammatory-drug-baricitinib-covid-19-begins (accessed on 23/05/20).
NIH. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/ accessed on
NIH. Isotretinoin in Treatment of COVID-19 (Randomized). https://clinicaltrials.gov/ct2/show/NCT04361422?cond=COVID 19&draw=2&rank=9 (accessed on 23/05/20).
WHO. COVID-19 vaccines. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines (accessed on 22/12/20)
FDA. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine (accessed on 22/12/20).
FDA. Moderna COVID-19 Vaccine. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine#additional (accessed on 22/12/20).
Letter from Additional Secretary, MoHFW regarding Contraindications and Factshe. https://www.mygov.in/covid-advisories/letter-additional-secretary-mohfw-regarding-contraindications-and-factsheet-covid/ (accessed on 21/01/20021)
Ministry of Health & Family Welfare Government of India. Covid 19 Vaccines Operational Guidelines. https://www.mohfw.gov.in/pdf/COVID19VaccineOG111Chapter16.pdf (accessed on 22/01/21).
Regulatory guidelines for development of vaccines with special consideration for COVID-19 vaccine, https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPublic_NoticesFiles/Regulatory_guidelines_for__development_of_Vaccine_20.9.20.pdf (accessed on 21.09.2020).
New Drugs and Clinical Trials Rules, 2019 published on 19/03/2019, https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/NewDrugs_CTRules_2019.pdf
Centers for Disease Control. What You Need to Know About Variants. https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant.html(accessed on 30/01/21).
Centers for Disease Control. Variant Proportions. https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant-cases.html (accessed on 30/01/21).
Centers for Disease Control. Variants and Genomic Surveillance for SARS-CoV-2. https://www.cdc.gov/coronavirus/2019-ncov/more/scientific-brief-emerging-variant.html (accessed on 30/01/21).
Refbacks
- There are currently no refbacks.
Copyright (c) 2022 Research & Reviews: A Journal of Immunology